On July 5, 2023, Pulmongene Ltd. announced that its investigational drug PMG1015 has completed the first administration in a patient with idiopathic pulmonary fibrosis (IPF) at the China-Japan Friendship Hospital.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib clinical trial aimed at evaluating the safety, tolerability, and pharmacokinetics of multiple doses of PMG1015 in IPF patients. The study is led by the China-Japan Friendship Hospital and plans to recruit 30 patients with IPF across six research centers nationwide. This marks a significant advancement for Pulmongene in the development of new drugs, with the hope of providing new treatment options for IPF patients.
“We are pleased to have completed the enrollment and administration of the first IPF patient at the China-Japan Friendship Hospital, marking an important step forward in the clinical development of PMG1015,” said Dr. Nan Tang, the founder of Pulmongene. “We hope that PMG1015 can fundamentally delay the progression of IPF in patients and greatly improve their survival time and quality of life. Pulmongene remains committed to a patient-centered approach and will fully promote the clinical development plan for PMG1015 in the future, aiming to quickly bring safe and effective new treatment options to IPF patients worldwide.”